How the issue of affordability is addressed around Europe was discussed at the Association of the British Pharmaceutical Industry’s (ABPI) annual conference in London yesterday.
Richard Torbett, chief economist of the European Federation of Pharmaceutical Industries and Associations (EFPIA), spoke about the challenge of affording medicines in Europe. He said that while pharmaceutical expenditure is growing, it’s lagging behind growth in total health care.
Dr Torbett said that the medicines price index is declining driven by a very efficient generics market. This is especially the case in the UK compared to the rest of Europe where there is a particularly efficient off-patent sector and a long-standing and persistent problem with the uptake of new medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze